UY38480A - Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides - Google Patents

Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Info

Publication number
UY38480A
UY38480A UY0001038480A UY38480A UY38480A UY 38480 A UY38480 A UY 38480A UY 0001038480 A UY0001038480 A UY 0001038480A UY 38480 A UY38480 A UY 38480A UY 38480 A UY38480 A UY 38480A
Authority
UY
Uruguay
Prior art keywords
amino acids
variability
reduce
acilated
cannabinoids
Prior art date
Application number
UY0001038480A
Other languages
English (en)
Inventor
Leone-Bay Andrea
Gregory Wesner
Original Assignee
Receptor Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Holdings Inc filed Critical Receptor Holdings Inc
Publication of UY38480A publication Critical patent/UY38480A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación provee el uso de aminoácidos grasos N-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides.
UY0001038480A 2018-11-19 2019-11-19 Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides UY38480A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862769395P 2018-11-19 2018-11-19

Publications (1)

Publication Number Publication Date
UY38480A true UY38480A (es) 2020-06-30

Family

ID=70774480

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038480A UY38480A (es) 2018-11-19 2019-11-19 Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Country Status (9)

Country Link
US (2) US12303487B2 (es)
EP (1) EP3883595A4 (es)
JP (2) JP7566336B2 (es)
AR (1) AR117118A1 (es)
AU (1) AU2019385420A1 (es)
CA (1) CA3120001A1 (es)
MX (1) MX2021005807A (es)
UY (1) UY38480A (es)
WO (1) WO2020106767A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2025046488A1 (en) * 2023-08-30 2025-03-06 BT DE Investments Inc. Synthetic cannabinoids for use in therapy and for enhancement of wellbeing

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385365A (en) 1943-02-17 1945-09-25 Wisconsin Alumni Res Found Salicylic acid compounds for safer therapeutic use
US3939259A (en) 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
DE2537232B2 (de) 1974-08-22 1976-07-01 Spritz- und formmasse
US4374082A (en) 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
ES2039226T3 (es) 1986-12-30 1993-09-16 American Cyanamid Company Procedimiento para preparar composiciones que contienen policarbofil.
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4902513A (en) 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US5965162A (en) 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
EP1049474A4 (en) 1998-11-24 2004-12-29 Univ Connecticut CANNABIMIMETIC LIPID AMIDES FOR USE AS MEDICINES
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
WO2001019901A2 (en) 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
EP1231273A1 (en) 2001-02-12 2002-08-14 Plant Research International B.V. Terpene synthase/cyclase and olefin synthase and uses thereof
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
IL143318A0 (en) 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
CA2466863A1 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2507815A1 (en) 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2004296877A1 (en) 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
US20050191349A1 (en) 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
IL162636A0 (en) 2004-06-20 2005-11-20 Yissum Res Dev Co Resorcinol derivatives and their use for lowering blood pressure
CN101076324A (zh) 2004-10-22 2007-11-21 法玛氏公司 口服有效的大麻素类似物
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP1893753B1 (en) 2005-06-17 2015-12-23 Firmenich Sa Novel sesquiterpene synthases and methods of their use
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20070104741A1 (en) 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
UY30090A1 (es) 2006-01-16 2007-08-31 Syngenta Participations Ag Insecticidas novedosos
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
CA2662123C (en) 2006-08-30 2015-12-01 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
GB0624340D0 (en) 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
EP2139333A4 (en) 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090155392A1 (en) 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009100245A1 (en) 2008-02-05 2009-08-13 Emisphere Technologies Inc. Low dose hmg-coa reductase inhibitor with reduced side effects
US20110137040A1 (en) 2008-08-01 2011-06-09 Lange Josephus H M Synthesis of 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamidine derivatives
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
CN101439074B (zh) 2008-12-11 2012-06-06 深圳海王药业有限公司 苍术总萜醇提取物及其制备方法和用途
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
SG190024A1 (en) 2010-11-25 2013-06-28 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
ES2806034T3 (es) 2011-09-29 2021-02-16 Thc Pharm Gmbh The Health Concept Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
US20150050373A1 (en) 2012-03-13 2015-02-19 Piramal Enterprises Limited Herbal composition for the treatment of metabolic disorders
WO2013165251A1 (en) 2012-05-03 2013-11-07 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising /\9-tetrahydrocannabinol and a method for preparing such an isolate
EP2666461B1 (en) 2012-05-23 2015-07-01 Tergum S.L. Terpene extract for the treatment of hair loss
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
CA3012383C (en) 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosynthesis of cannabinoids
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
MX2015011896A (es) 2013-03-15 2016-07-19 Korea United Pharm Inc Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US9326967B2 (en) 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US9532593B2 (en) 2013-12-26 2017-01-03 John Turner Herbal smoking blend
WO2015118549A1 (en) 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
CA2845443A1 (en) 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2016205923A1 (en) 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
BR112018071518A2 (pt) * 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. compostos medicinais à base de planta de ação rápida e suplementos nutricionais
CN116850132A (zh) * 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20190336472A1 (en) 2017-01-03 2019-11-07 Receptor Holdings, Inc. Medicinal compounds and nutritional supplements
AU2018233582B2 (en) * 2017-03-16 2022-04-07 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
BR112019019776A2 (pt) 2017-03-23 2020-04-22 Receptor Holdings, Inc. entrega rápida e controlada de composições com efeitos entourage restaurados
JP2020536858A (ja) 2017-10-05 2020-12-17 レセプター・ホールディングス・インコーポレイテッド 改善されたバイオアベイラビリティーを有するハーブ組成物
CA3078549A1 (en) 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations

Also Published As

Publication number Publication date
MX2021005807A (es) 2021-07-02
JP7566336B2 (ja) 2024-10-15
US12303487B2 (en) 2025-05-20
AR117118A1 (es) 2021-07-14
EP3883595A1 (en) 2021-09-29
CA3120001A1 (en) 2020-05-28
JP2022507730A (ja) 2022-01-18
WO2020106767A1 (en) 2020-05-28
AU2019385420A1 (en) 2021-07-08
US20250268861A1 (en) 2025-08-28
EP3883595A4 (en) 2022-12-14
US20210393575A1 (en) 2021-12-23
JP2024178417A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
CL2018002081A1 (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
UY37920A (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
GT200600074A (es) 5-alcoxialquil-6-alquil-7-amino-azolopirimidinas, un procedimiento para su obtención y el uso de las mismas para combatir hongos nocivos, así como procuctos que las mismas contienen
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX2021006977A (es) Anellosomas y metodos de uso.
EA202090889A1 (ru) Травяные композиции с улучшенной биодоступностью
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2018016096A (es) Anticuerpos antagonistas de anti-axl.
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112017011476A2 (pt) composição baseada em aminoácidos para recuperação de fibroelastina em tecidos conjuntivos dérmicos e uso
SV2017005517A (es) Composición acida a base de leonardita y aminoácidos
CL2019003557A1 (es) Anticuerpos anti-trkb.
ECSP17011248A (es) Uso de señales visuales para mejorar composiciones repelentes de aves
CL2020002268A1 (es) Métodos para mejorar el rendimiento en rumiantes
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CL2019002629A1 (es) Análogos de deutetrabenazina, su preparación y uso.
CL2022001612A1 (es) Tieniloxazolonas y análogos
MX2020004748A (es) Composiciones y metodos para mejorar el uso de fosforo y calcio de la dieta en animales.
UY38480A (es) Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
BR112019003915A2 (pt) composição para tratamento dos cabelos, método de tratamento de cabelo danificado quimicamente e usos de uma composição
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
GT201700228A (es) Uso de un aditivo de combustible en combustible diésel para reducir el consumo de combustible en un motor diésel

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240610